Compare TYL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYL | NBIX |
|---|---|---|
| Founded | 1966 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 13.2B |
| IPO Year | 1996 | 1996 |
| Metric | TYL | NBIX |
|---|---|---|
| Price | $321.49 | $130.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $474.36 | $180.82 |
| AVG Volume (30 Days) | 423.2K | ★ 901.1K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.01 | ★ 41.95 |
| EPS | ★ 7.20 | 4.67 |
| Revenue | ★ $493,101,000.00 | $161,626,000.00 |
| Revenue This Year | $9.59 | $22.85 |
| Revenue Next Year | $9.70 | $10.36 |
| P/E Ratio | $44.59 | ★ $27.09 |
| Revenue Growth | 18.35 | ★ 977.51 |
| 52 Week Low | $283.72 | $97.30 |
| 52 Week High | $621.34 | $160.18 |
| Indicator | TYL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 49.52 |
| Support Level | $283.72 | $124.29 |
| Resistance Level | $365.00 | $136.23 |
| Average True Range (ATR) | 11.09 | 4.29 |
| MACD | -1.38 | -0.10 |
| Stochastic Oscillator | 20.09 | 55.93 |
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.